Efficacy of N-Acetylcysteine on Liver Function and Metabolic Profiles in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Double-Blind, Randomized Controlled Trial

Document Type : Original Article

Authors

1 Department of Internal Medicine, Kashan University of Medical Sciences, Kashan, Iran

2 Faculty of Medicine, Bogomolets National Medical University (NMU), Kyiv, Ukraine

3 Department of Hematology-Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences (TUMS), Tehran, Iran

4 Faculty of Medicine, Hamadan University of Medical Sciences (UMSHA), Hamadan, Iran

5 Faculty of Medicine, Islamic Azad University, Tehran Medical Sciences Branch (IAUTMU), Tehran, Iran

6 School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran

7 Sina Hospital, Department of Internal Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran

10.34172/ahj.1667

Abstract

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as non-alcoholic fatty liver disease (NAFLD), is a common liver disorder associated with metabolic abnormalities. This study aimed to evaluate the effectiveness of N-acetylcysteine (NAC) in improving liver function and metabolic profile in patients with MASLD.
Methods: In this randomized controlled trial (RCT), 69 patients with MASLD were randomly assigned to either the NAC group (600 mg, administered three times daily, n = 34) or the placebo group (n = 35) for eight weeks. The severity of hepatic steatosis, liver enzymes, and metabolic profile were measured at baseline and the final trial. Data were analyzed using SPSS.
Findings: Following eight weeks of NAC administration in patients with MASLD, no significant changes were observed compared to the placebo in hepatic steatosis grade (P = 0.215), serum aspartate aminotransferase (AST) (P = 0.21), alanine transaminase (ALT) (P = 0.28), malondialdehyde (MDA) (P = 0.79), total antioxidant capacity (TAC) (P = 0.56), triglycerides (P = 0.15), total cholesterol (P = 0.28), low-density lipoprotein cholesterol (P = 0.32), and high-density lipoprotein cholesterol (P = 0.16). However, NAC administration resulted in significant reductions in fasting blood glucose (FBG) (P = 0.01), fasting insulin levels (P < 0.001), homeostatic model assessment for insulin resistance (HOMA-IR) (P < 0.001), and C-reactive protein (CRP) (P < 0.001), along with a significant increase in total glutathione levels (P = 0.003), compared to the placebo group.
Conclusion: NAC administration in patients with MASLD does not significantly impact hepatic steatosis, liver enzymes, or lipid profiles; however, it improves oxidative, glycemic, and inflammatory markers. Therefore, NAC may be a beneficial adjunct therapy for managing metabolic parameters and reducing inflammation and oxidative stress in MASLD patients.
Trial Registration: The trial was registered with the Iranian Registry of Clinical Trials (IRCT20201220049772N1) on February 20, 2021.

Highlights

Mehdi Karimi(Google Scholar)(Pubmed)

Keywords

References

  1. Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. J Obes Metab Syndr. 2023;32(3):197-213. doi: 10.7570/jomes23052.
  2. Samy AM, Kandeil MA, Sabry D, Abdel-Ghany AA, Mahmoud MO. From NAFLD to NASH: understanding the spectrum of non-alcoholic liver diseases and their consequences. Heliyon. 2024;10(9):e30387. doi: 10.1016/j.heliyon.2024.e30387.
  3. Thomas JA, Kendall BJ, El-Serag HB, Thrift AP, Macdonald GA. Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol. 2024;9(2):159-69. doi: 10.1016/s2468-1253(23)00275-3.
  4. Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851-61. doi: 10.1016/ s2468-1253(22)00165-0.
  1. Tabaeian SP, Rezapour A, Azari S, Martini M, Saran M, Behzadifar M, et al. Prevalence of non-alcoholic fatty liver disease in Iran: a systematic review and meta-analysis. J Clin Exp Hepatol. 2024;14(1):101209. doi: 10.1016/j. jceh.2023.06.009.
  2. Lim S, Kim JW, Targher G. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab. 2021;32(7):500-14. doi: 10.1016/j. tem.2021.04.008.
  3. Stefan N, Yki-Järvinen H, Neuschwander-Tetri BA. Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. Lancet Diabetes Endocrinol. 2025;13(2):134-48. doi: 10.1016/s2213-8587(24)00318-8.
  4. Kravchuk S, Bychkov M, Kozyk M, Strubchevska O, Kozyk A. Managing metabolic dysfunction-associated steatotic liver disease (MASLD) in the digital era: overcoming barriers to lifestyle change. Cureus. 2025;17(5):e84803. doi: 10.7759/ cureus.84803.
  5. Mohammadian K, Fakhar F, Keramat S, Stanek A. The role of antioxidants in the treatment of metabolic dysfunction-associated fatty liver disease: a systematic review. Antioxidants (Basel). 2024;13(7):797. doi: 10.3390/antiox13070797.
  6. Dos Santos Tenório MC, Graciliano NG, Moura FA, de Oliveira AC, Goulart MO. N-acetylcysteine (NAC): impacts on human health. Antioxidants (Basel). 2021;10(6):967. doi: 10.3390/antiox10060967.
  7. Schwalfenberg GK. N-acetylcysteine: a review of clinical usefulness (an old drug with new tricks). J Nutr Metab. 2021;2021:9949453. doi: 10.1155/2021/9949453.
  8. Hang W, Shu H, Wen Z, Liu J, Jin Z, Shi Z, et al. N-acetyl cysteine ameliorates high-fat diet-induced nonalcoholic fatty liver disease and intracellular triglyceride accumulation by preserving mitochondrial function. Front Pharmacol. 2021;12:636204. doi: 10.3389/fphar.2021.636204.
  9. Nikbaf-Shandiz M, Adeli S, Faghfouri AH, Khademi F, Jamilian P, Zarezadeh M, et al. The efficacy of N-acetylcysteine in improving liver function: a systematic review and meta-analysis of controlled clinical trials. PharmaNutrition. 2023;24:100343. doi: 10.1016/j.phanu.2023.100343.
  10. Khoshbaten M, Aliasgarzadeh A, Masnadi K, Tarzamani MK, Farhang S, Babaei H, et al. N-acetylcysteine improves liver function in patients with non-alcoholic fatty liver disease. Hepat Mon. 2010;10(1):12-6.
  11. Calverley P, Rogliani P, Papi A. Safety of N-acetylcysteine at high doses in chronic respiratory diseases: a review. Drug Saf. 2021;44(3):273-90. doi: 10.1007/s40264-020-01026-y.
  12. Raghu G, Berk M, Campochiaro PA, Jaeschke H, Marenzi G, Richeldi L, et al. The multifaceted therapeutic role of N-acetylcysteine (NAC) in disorders characterized by oxidative stress. Curr Neuropharmacol. 2021;19(8):1202-24. doi: 10.2174/1570159x19666201230144109.
  13. Schuurman M, Wallace M, Sahi G, Barillaro M, Zhang S, Rahman M, et al. N-acetyl-L-cysteine treatment reduces beta-cell oxidative stress and pancreatic stellate cell activity in a high fat diet-induced diabetic mouse model. Front Endocrinol (Lausanne). 2022;13:938680. doi: 10.3389/ fendo.2022.938680.
  14. Falach-Malik A, Rozenfeld H, Chetboun M, Rozenberg K, Elyasiyan U, Sampson SR, et al. N-acetyl-L-cysteine inhibits the development of glucose intolerance and hepatic steatosis in diabetes-prone mice. Am J Transl Res. 2016;8(9):3744-56.
  15. Oka S, Kamata H, Kamata K, Yagisawa H, Hirata H. N-acetylcysteine suppresses TNF-induced NF-kappaB activation through inhibition of IkappaB kinases. FEBS Lett. 2000;472(2- 3):196-202. doi: 10.1016/s0014-5793(00)01464-2.
  16. Santus P, Signorello JC, Danzo F, Lazzaroni G, Saad M, Radovanovic D. Anti-inflammatory and anti-oxidant properties of N-acetylcysteine: a fresh perspective. J Clin Med. 2024;13(14):4127. doi: 10.3390/jcm13144127.
  17. Skrzydlewska E, Farbiszewski R. Protective effect of N-acetylcysteine on reduced glutathione, reduced glutathione-related enzymes and lipid peroxidation in methanol intoxication. Drug Alcohol Depend. 1999;57(1):61- 7. doi: 10.1016/s0376-8716(99)00040-x.
  18. Pedre B, Barayeu U, Ezeriņa D, Dick TP. The mechanism of action of N-acetylcysteine (NAC): the emerging role of H2S and sulfane sulfur species. Pharmacol Ther. 2021;228:107916. doi: 10.1016/j.pharmthera.2021.107916.
  19. Richard D, Kefi K, Barbe U, Bausero P, Visioli F. Polyunsaturated fatty acids as antioxidants. Pharmacol Res. 2008;57(6):451-5. doi: 10.1016/j.phrs.2008.05.002.
  20. Yang K, Kim HH, Shim YR, Ryu T, Kim CW. Comprehensive transcriptomic analysis and meta-analysis identify therapeutic effects of N-acetylcysteine in nonalcoholic fatty liver disease. Front Pharmacol. 2023;14:1186582. doi: 10.3389/ fphar.2023.1186582.
  21. Cetinkaya A, Kantarceken B, Bulbuloglu E, Kurutas EB, Ciralik H, Atli Y. The effects of L-carnitine and N-acetylcysteine on carbontetrachloride induced acute liver damage in rats. Bratisl Lek Listy. 2013;114(12):682-8. doi: 10.4149/bll_2013_145.
  22. Babu Balagopal P, Kohli R, Uppal V, Averill L, Shah C, McGoogan K, et al. Effect of N-acetyl cysteine in children with metabolic dysfunction-associated steatotic liver disease-a pilot study. J Pediatr Gastroenterol Nutr. 2024;79(3):652-60. doi: 10.1002/jpn3.12312.
  23. Pamuk GE, Sonsuz A. N-acetylcysteine in the treatment of non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2003;18(10):1220-1. doi: 10.1046/j.1440-1746.2003.03156.x.
  24. Rani M, Aggarwal R, Vohra K. Effect of N-acetylcysteine on metabolic profile in metabolic syndrome patients. Metab Syndr Relat Disord. 2020;18(7):341-6. doi: 10.1089/ met.2020.0017.
  25. Fulghesu AM, Ciampelli M, Muzj G, Belosi C, Selvaggi L, Ayala GF, et al. N-acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome. Fertil Steril. 2002;77(6):1128-35. doi: 10.1016/s0015- 0282(02)03133-3.
  26. de Oliveira CP, Stefano JT, de Siqueira ER, Silva LS, de Campos Mazo DF, Lima VM, et al. Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. Hepatol Res. 2008;38(2):159-65. doi: 10.1111/j.1872-034X.2007.00215.x.
  27. Dludla PV, Nkambule BB, Mazibuko-Mbeje SE, Nyambuya TM, Marcheggiani F, Cirilli I, et al. N-acetyl cysteine targets hepatic lipid accumulation to curb oxidative stress and inflammation in NAFLD: a comprehensive analysis of the literature. Antioxidants (Basel). 2020;9(12):1283. doi: 10.3390/antiox9121283.
  28. Calzadilla P, Sapochnik D, Cosentino S, Diz V, Dicelio L, Calvo JC, et al. N-acetylcysteine reduces markers of differentiation in 3T3-L1 adipocytes. Int J Mol Sci. 2011;12(10):6936-51. doi: 10.3390/ijms12106936.
  29. Qiu Y, Yu H, Zeng R, Guo S, Daniyal M, Deng Z, et al. Recent development on anti-obesity compounds and their mechanisms of action: a review. Curr Med Chem. 2020;27(21):3577-97. doi: 10.2174/0929867326666190215 114359.
  30. Sohouli MH, Eslamian G, Malekpour Alamdari N, Abbasi M, Fazeli Taherian S, Behtaj D, et al. Effects of N-acetylcysteine on aging cell and obesity complications in obese adults: a randomized, double-blind clinical trial. Front Nutr. 2023;10:1237869. doi: 10.3389/fnut.2023.1237869.
  31. Jeremias A, Soodini G, Gelfand E, Xu Y, Stanton RC, Horton ES, et al. Effects of N-acetyl-cysteine on endothelial function and inflammation in patients with type 2 diabetes mellitus. Heart Int. 2009;4(1):e7. doi: 10.4081/hi.2009.e7.
  32. Sayed E, Gaballah K, Younis E, Yassen K, El-Einen AK. The effect of intravenous infusion of N-acetyl cysteine in cirrhotic patients undergoing liver resection: a randomized controlled trial. J Anaesthesiol Clin Pharmacol. 2017;33(4):450-6. doi: 10.4103/joacp.JOACP_70_17.
Addiction & Health
Volume 17
Pages 1-9

Files

Share

How to cite

Statistics